Norvir/Invirase Go Head-to-Head with Kaletra
Early results from a 48-week clinical trial comparing Norvir (ritonavir)-boosted Invirase (saquinavir) to Kaletra (lopinavir plus ritonavir) suggest that both options are working similarly well in patients starting therapy for the first time, although the rate of virologic failure has thus far been higher in the Norvir/Invirase group.
Starting or Switching: Truvada Outpaces Combivir in Studies Researchers have reported extended follow-up data from a clinical trial comparing two pairs of nucleoside reverse transcriptase inhibitors (NRTIs), both combined with Sustiva (efavirenz): once-daily Truvada (tenofovir plus lamivudine) plus Emtriva (emtricitabine) versus Combivir (zidovudine plus lamivudine).
Is HIV Treatment Actually Reducing Heart Attack Risk? New study data reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention indicates that HIV treatment—despite its often negative effects on blood lipid levels—may actually reverse artery hardening that can lead to a heart attack or stroke.
Sustiva Edges Out Celsentri in Treatment Newbies
A clinical trial has found that Pfizer's CCR5-blocking entry inhibitor, Celsentri (maraviroc), when used by patients starting HIV treatment for the first time, appears somewhat inferior to standard-of-care Sustiva (efavirenz).
Simple Test Can Help Prevent Abacavir Allergy A clinical trial has confirmed that a simple lab test for a human gene can help prevent a serious allergic reaction caused by abacavir, the active ingredient in Ziagen and a component of Epzicom (Kivexa) and Trizivir.
High Risk of Kidney Problems in HIV
There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney.
Simple Test Eliminates Abacavir Risk
Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
Vicriviroc Shows Benefits, Continues Development
The AIDS Clinical Trials Group has reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in the Phase II stage of development.
A Positive Papua New Guinean Speaks Out Against Stigma
Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
Timed Intercourse Plus PrEP for Low-Risk Natural Conception
HIV-negative women who use pre-exposure prophylaxis (PrEP) immediately prior to engaging in carefully timed sexual intercourse with their antiretroviral-treated HIV-positive male partners may further reduce their already low risk of being exposed to the virus.
Celsentri (Maraviroc) Interaction Warning
Based on a recent drug interaction study, Pfizer is warning that the dose of Celsentri (maraviroc) needs to be altered if the drug is combined with Tibotec’s etravirine and/or Prezista.
AIDS Down Under: IAS Conference Begins in Sydney
The IAS Conference on HIV Pathogenesis, Treatment
and Prevention began with calls
for even greater vigilance to ensure universal access to HIV prevention
and treatment, along with an expansion of research to inform and
strengthen the global response to HIV.
Fauci Defends Bush's AIDS Legacy
Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
July 20, 2007
No Lipodystrophy Approval for Serostim
The Food and Drug Administration (FDA) declined this week to approve EMD Serono’s Serostim for the treatment of HIV-associated adipose redistribution syndrome (HARS)—the accumulation of fat associated with lipodystrophy. As a result, patient access to the drug for HARS will likely be difficult to secure.
Dynamic Duo Etravirine and Prezista Shine in Studies
Data from two ongoing Phase III studies indicate that Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (TMC-125), combined with their approved protease inhibitor (PI) Prezista (darunavir), packs a powerful antiviral punch in HIV-positive patients with documented NNRTI and PI resistance.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to firstname.lastname@example.org.